Relmada Therapeutics (RLMD) EBITDA Margin (2012 - 2013)
Relmada Therapeutics (RLMD) reported EBITDA Margin of 776.97% for Q4 2013, down 35724.0% year-over-year from N/an in Q4 2012, and up 74.72% quarter-over-quarter from 3073.34% in Q2 2013.
Relmada Therapeutics (RLMD) EBITDA Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of EBITDA Margin data on file, last reported at 776.97% in Q4 2013.
- EBITDA Margin for Q4 2013 came in at 776.97%, down 35724.0% year-over-year; the trailing twelve-month figure through Nov 2013 was 786.85% (changed N/A YoY), and the FY2013 annual result was 877.66%, down 72589.0% from the prior year.
- EBITDA Margin climbed to 776.97% in Q4 2013 per RLMD's latest filing, from 3073.34% in the prior quarter.
- Over five years, EBITDA Margin peaked at 176.73% in Q1 2013 and troughed at 3073.34% in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Relmada Therapeutics | 575.00 Mn | 575.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -776.97% |
| May 31, 2013 | -3,073.34% |
| Feb 28, 2013 | -176.73% |
| Nov 30, 2012 | -419.73% |
| Aug 31, 2012 | -569.57% |
| May 31, 2012 | -620.25% |